← FDA DRUG APPROVALS

FDA BLA · BLA761452

IMMGOLIS

Sponsor: ACCORD BIOPHARMA INC.

APPLICATION
BLA761452
TYPE
BLA
ORIGINAL APPROVAL
2026-05-15
LATEST ACTION
2026-05-15
ROUTE
SOLUTION
DOSAGE FORM
INJECTION
MARKETING STATUS
Prescription

Products

IMMGOLISPrescription
GOLIMUMAB-SLDI 100MG/1ML · INJECTION · SOLUTION
IMMGOLIS INTRIPrescription
GOLIMUMAB-SLDI 50MG/4ML · INJECTION · SOLUTION
IMMGOLISPrescription
GOLIMUMAB-SLDI 50MG/0.5ML · INJECTION · SOLUTION

Approval history

2026-05-15Type 5 - New Formulation or New Manufacturer · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →